Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Histologically documented diagnosis of GIST~* Resectable GIST~* GIST removed at open surgery~* Immunohistochemical documentation of GIST (immunostaining for KIT/CD117)~* High risk of tumor recurrence as defined as one of the following: 1) the largest tumor diameter greater than 10.0 cm (measured by a pathologist, with any mitotic count); 2) mitotic count over 10 mitoses per 50 high power fields (HPFs) (with any tumor size); the largest tumor diameter larger than 5.0 cm and the mitotic count is over 5/50 HPFs; 4) tumor spillage into the abdominal cavity at surgery (or tumor rupture). No residual tumors must be present at laparotomy, or in postoperative CT or MRI examinations. Patients who have microscopically infiltrated margins (or suspected microscopical infiltration, R1) are also allowed to enter study.~* Performance status 0, 1, or 2 (ECOG)~* Adequate organ function, defined as follows: total bilirubin \<1.5 x ULN (upper limit of normal), serum AST (SGOT) and ALT (SGPT) \<2.5 x ULN, creatinine \<1.5 x ULN, ANC (neutrophil count) \>1.5 x 10\^9/L, platelets \>100 x 10\^9/L.~* Negative pregnancy test (females with childbearing potential)~* Written, voluntary informed consent~Exclusion Criteria:~* Inoperable or metastatic GIST~* Less than 1 week or more than 12 weeks has elapsed from surgery~* Recurrent GIST~* Patient has received any investigational agents within 28 days as calculated from the first day of the study drug dosing~* Patient is less than 5 years free from another primary malignancy~* Patient with grade III/IV cardiac problems as defined by the New York Heart Association Criteria~* Female patients who are pregnant or breast-feeding~* Patient has severe or uncontrolled medical disease (i.e. uncontrolled diabetes, severe chronic renal disease, or active uncontrolled infection). Concurrent use of warfarin or acetaminophen are not allowed with imatinib.~* Chronic liver disease~* Known diagnosis of human immunodeficiency virus (HIV) infection~* Patient has received chemotherapy for GIST~* Patient has received neoadjuvant imatinib therapy prior to randomization~* Radiotherapy to 25% or more of the bone marrow~* Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 1 year of adjuvant imatinib mesylate 400 mg/day orally
- 2 (Type: EXPERIMENTAL): 3 years of adjuvant imatinib mesylate 400 mg/day orally

Based on this trial design, predict the completion outcome and termination type (if applicable).